{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "cd365676-8285-4bfc-a1fe-93fd31ff92cb",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "def read_file(file):\n",
    "\twith open(file, \"r\") as fp:\n",
    "\t    data = json.load(fp)\n",
    "\treturn data\n",
    "biomarkers = read_file(\"data/copy-biomarkers.json\")\n",
    "indications = read_file(\"data/indications.json\")\n",
    "therapies = read_file(\"data/copy-therapies.json\")\n",
    "diseases = read_file(\"data/copy-diseases.json\")\n",
    "propositions = read_file(\"data/propositions.hc.json\")\n",
    "contributions = read_file(\"data/copy-contributions.json\")\n",
    "strength = read_file(\"data/copy-strengths.json\")\n",
    "documents = read_file(\"data/documents.json\")\n",
    "statements = read_file(\"data/statements.hc.json\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "id": "6a751d62-44dd-465a-acc2-1acc8943e634",
   "metadata": {},
   "outputs": [],
   "source": [
    "therapy_lookup = {item[\"id\"]: item for item in therapies}\n",
    "disease_lookup = {item[\"id\"]: item for item in diseases}\n",
    "biomarker_lookup = {item[\"id\"]: item for item in biomarkers}\n",
    "strength_lookup = {item[\"id\"]: item for item in strength}\n",
    "contribution_lookup = {item[\"id\"]: item for item in contributions}\n",
    "document_lookup = {doc[\"id\"]: doc for doc in documents}\n",
    "indication_lookup = {ind[\"id\"]: ind for ind in indications}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "id": "56022c16-68c6-4ece-82fa-60a1333372b7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup):\n",
    "    dereferenced_props = []\n",
    "    for prop in propositions:\n",
    "        prop = prop.copy()\n",
    "        \n",
    "        therapy_id = prop.pop(\"therapy_id\")\n",
    "        prop[\"therapy\"] = therapy_lookup[therapy_id]\n",
    "\n",
    "        condition_id = prop.pop(\"conditionQualifier_id\")\n",
    "        prop[\"conditionQualifier\"] = disease_lookup[condition_id]\n",
    "\n",
    "        resolved_biomarkers = []\n",
    "        for bio in prop[\"biomarkers\"]:\n",
    "            resolved_biomarkers.append(biomarker_lookup[bio])\n",
    "        prop[\"biomarkers\"] = resolved_biomarkers\n",
    "\n",
    "        dereferenced_props.append(prop)\n",
    "    return dereferenced_props"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "id": "cb939ca0-bf87-46aa-aabd-1fbce5b9594e",
   "metadata": {},
   "outputs": [],
   "source": [
    "#print(dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "id": "7a1f7792-d055-41c8-a827-ae8938925bfd",
   "metadata": {},
   "outputs": [],
   "source": [
    "dereferenced_props = dereference_propositions(propositions, therapy_lookup, disease_lookup, biomarker_lookup)\n",
    "dereferenced_prop_lookup = {prop[\"id\"]: prop for prop in dereferenced_props}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "id": "10a52b00-7170-4328-a5b4-3eb202a658ce",
   "metadata": {},
   "outputs": [],
   "source": [
    "   def dereference_statements(statements, proposition_lookup, strength_lookup, indication_lookup, contribution_lookup, document_lookup):\n",
    "    dereferenced_statements = []\n",
    "    for state in statements:\n",
    "        state = state.copy()\n",
    "\n",
    "        proposition_id = state.pop(\"proposition_id\")\n",
    "        state[\"proposition\"] = proposition_lookup[proposition_id]\n",
    "\n",
    "        strength_id = state.pop(\"strength_id\")\n",
    "        state[\"strength\"] = strength_lookup[strength_id]\n",
    "\n",
    "        indication_id = state.pop(\"indication_id\")\n",
    "        state[\"indication\"] = indication_lookup[indication_id]\n",
    "\n",
    "        contributions_resolved = []\n",
    "        for contrib_id in state[\"contributions\"]:\n",
    "            contributions_resolved.append(contribution_lookup[contrib_id])\n",
    "        state[\"contributions\"] = contributions_resolved\n",
    "\n",
    "        documents_resolved = []\n",
    "        for doc_id in state[\"reportedIn\"]:\n",
    "            documents_resolved.append(document_lookup[doc_id])\n",
    "        state[\"reportedIn\"] = documents_resolved\n",
    "\n",
    "        dereferenced_statements.append(state)\n",
    "    return dereferenced_statements   "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "id": "fb0c9eaf-d5b1-4b55-8756-80435bde4291",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'id': 0, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.alecensaro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alecensaro (alectinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Alecensaro (alectinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078825.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Alecensaro', 'drug_name_generic': 'alectinib', 'first_published': '2016-09-29', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-03-11', 'url': 'https://pdf.hres.ca/dpd_pm/00078825.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 0, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 8, 'type': 'CategoricalVariant', 'name': 'v::ALK', 'genes': [2], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 9, 'conceptType': 'Drug', 'name': 'Alectinib', 'primary_coding_id': 'ncit:C101790', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.alecensaro:0', 'document_id': 'doc:hc.alecensaro', 'indication': 'ALECENSARO (alectinib) is indicated for the first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved alectinib for the first-line treatment of patients with ALK-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative therapy.', 'raw_biomarkers': 'ALK-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer', 'raw_therapeutics': 'Alecensaro (alectinib)'}}, {'id': 1, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [product monograph]. HC.', 'aliases': [], 'citation': 'AstraZeneca Canada Inc. Faslodex (fulvestrant) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00053975.PDF. Revised November 2019. Accessed June 2025.', 'company': 'AstraZeneca Canada Inc.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-11-15', 'url': 'https://pdf.hres.ca/dpd_pm/00053975.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72981', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 1, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 1, 'type': 'CategoricalVariant', 'name': 'ER positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 2, 'type': 'CategoricalVariant', 'name': 'HER2-negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primary_coding_id': 'ncit:C1379', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.faslodex:0', 'document_id': 'doc:hc.faslodex', 'indication': 'FASLODEX (fulvestrant) is indicated for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved fulvestrant for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.', 'raw_biomarkers': 'estrogen receptor-positive (ER+), HER2-negative', 'raw_cancer_type': 'locally advanced or metastatic breast cancer', 'raw_therapeutics': 'Faslodex (fulvestrant)'}}, {'id': 2, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.giotrif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Giotrif (afatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Boehringer Ingelheim (Canada) Ltd. Giotrif (afatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00051644.PDF. Revised June 2019. Accessed June 2025.', 'company': 'Boehringer Ingelheim (Canada) Ltd', 'drug_name_brand': 'Giotrif', 'drug_name_generic': 'afatinib', 'first_published': None, 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2019-06-06', 'url': 'https://pdf.hres.ca/dpd_pm/00051644.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90026', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 2, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 9, 'type': 'CategoricalVariant', 'name': 'EGFR p.L858R', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 21}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}, {'name': 'hgvsc', 'value': 'ENST00000275493.2:c.2573T>G'}, {'name': '_present', 'value': True}]}, {'id': 10, 'type': 'CategoricalVariant', 'name': 'EGFR Exon 19 (Deletion)', 'genes': [17], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': None}, {'name': 'end_position', 'value': None}, {'name': 'reference_allele', 'value': None}, {'name': 'alternate_allele', 'value': None}, {'name': 'cdna_change', 'value': None}, {'name': 'protein_change', 'value': None}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': 19}, {'name': 'rsid', 'value': None}, {'name': 'hgvsg', 'value': None}, {'name': 'hgvsc', 'value': None}, {'name': 'requires_oncogenic', 'value': True}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 34, 'conceptType': 'Drug', 'name': 'Afatinib', 'primary_coding_id': 'ncit:C66940', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.giotrif:0', 'document_id': 'doc:hc.giotrif', 'indication': 'GIOTRIF (afatinib) is indicated as monotherapy for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).', 'raw_biomarkers': 'EGFR Del 19, EGFR exon 21 L858R', 'raw_cancer_type': 'metastatic adenocarcinoma of the lung', 'raw_therapeutics': 'Giotrif (afatinib)'}}, {'id': 3, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.lumakras', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lumakras (sotorasib) [product monograph]. HC.', 'aliases': [], 'citation': 'Amgen Canada Inc. Lumakras (sotorasib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078781.PDF. Revised March 2025. Accessed June 2025.', 'company': 'Amgen Canada Inc.', 'drug_name_brand': 'Lumakras', 'drug_name_generic': 'sotorasib', 'first_published': '2021-09-09', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2025-03-04', 'url': 'https://pdf.hres.ca/dpd_pm/00078781.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100931', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 3, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 45, 'type': 'CategoricalVariant', 'name': 'KRAS p.G12C', 'genes': [31], 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '12'}, {'name': 'start_position', 'value': 25398285}, {'name': 'end_position', 'value': 25398285}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.34G>T'}, {'name': 'protein_change', 'value': 'p.G12C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': 2}, {'name': 'rsid', 'value': 'rs121913530'}, {'name': 'hgvsg', 'value': '12:g.25398285C>A'}, {'name': 'hgvsc', 'value': 'ENST00000256078.4:c.34G>T'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 57, 'conceptType': 'Drug', 'name': 'Sotorasib', 'primary_coding_id': 'ncit:C154287', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['RAS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.lumakras:0', 'document_id': 'doc:hc.lumakras', 'indication': 'LUMAKRAS (sotorasib) is indicated for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved sotorasib for the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.', 'raw_biomarkers': 'KRAS p.G12C', 'raw_cancer_type': 'locally advanced or metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Lumakras (sotorasib)'}}, {'id': 4, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Loxo Oncology Inc. Retevmo (selpercatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00078253.PDF. Revised January 2025. Accessed June 2025.', 'company': 'Loxo Oncology Inc.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2021-06-11', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2025-01-10', 'url': 'https://pdf.hres.ca/dpd_pm/00078253.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100625', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 4, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 18, 'type': 'CategoricalVariant', 'name': 'v::RET', 'genes': [49], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 78, 'conceptType': 'Drug', 'name': 'Selpercatinib', 'primary_coding_id': 'ncit:C134987', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 47, 'conceptType': 'Disease', 'name': 'Non-Small Cell Lung Cancer', 'primary_coding_id': 'oncotree:NSCLC', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.retevmo:0', 'document_id': 'doc:hc.retevmo', 'indication': 'RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved selpercatinib as monotherapy for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adult patients.', 'raw_biomarkers': 'RET fusion-positive', 'raw_cancer_type': 'metastatic non-small cell lung cancer (NSCLC)', 'raw_therapeutics': 'Retevmo (selpercatinib)'}}, {'id': 5, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.revlimid', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Revlimid (lenalidomide) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Revlimid', 'drug_name_generic': 'lenalidomide', 'first_published': '2024-02-09', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2024-02-09', 'url': 'https://pdf.hres.ca/dpd_pm/00074535.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79016', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 5, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 61, 'type': 'CategoricalVariant', 'name': '5q deletion', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number (arm level)'}, {'name': 'chromosome', 'value': '5'}, {'name': 'arm', 'value': 'q'}, {'name': 'direction', 'value': 'Deletion'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 79, 'conceptType': 'Drug', 'name': 'Lenalidomide', 'primary_coding_id': 'ncit:C2668', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Angiogenesis inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 43, 'conceptType': 'Disease', 'name': 'Myelodysplastic Syndromes', 'primary_coding_id': 'oncotree:MDS', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.revlimid:0', 'document_id': 'doc:hc.revlimid', 'indication': 'REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved lenalidomide for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogentic abnormalities.', 'raw_biomarkers': '5q deletion', 'raw_cancer_type': 'transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes', 'raw_therapeutics': 'Revlimid (lenalidomide)'}}, {'id': 6, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [product monograph]. HC.', 'aliases': [], 'citation': 'Hoffmann-La Roche Limited. Kadcyla (ado-trastuzumab emtansine) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00067729.PDF. Revised October 2022. Accessed June 2025.', 'company': 'Hoffmann-La Roche Limited', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': '2013-09-11', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2022-10-13', 'url': 'https://pdf.hres.ca/dpd_pm/00067729.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89698', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 6, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 52, 'conceptType': 'Drug', 'name': 'Trastuzumab emtansine', 'primary_coding_id': 'ncit:C82492', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.kadcyla:0', 'document_id': 'doc:hc.kadcyla', 'indication': 'KADCYLA (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.', 'raw_biomarkers': 'HER2-positive', 'raw_cancer_type': 'metastatic breast cancer', 'raw_therapeutics': 'Kadcyla (trastuzumab emtansine)'}}, {'id': 7, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.besponsa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Besponsa (inotuzumab ozogamicin) [product monograph]. HC.', 'aliases': [], 'citation': 'Pfizer Canada ULC. Besponsa (inotuzumab ozogamicin) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00077730.PDF. Revised November 2024. Accessed June 2025.', 'company': 'Pfizer Canada ULC', 'drug_name_brand': 'Besponsa', 'drug_name_generic': 'inotuzumab ozogamicin', 'first_published': '2018-03-15', 'access_date': '2025-06-12', 'organization_id': 'hc', 'publication_date': '2024-11-08', 'url': 'https://pdf.hres.ca/dpd_pm/00077730.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96383', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 7, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 13, 'type': 'CategoricalVariant', 'name': 'CD22 +', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'CD22'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 14, 'conceptType': 'Drug', 'name': 'Inotuzumab ozogamicin', 'primary_coding_id': 'ncit:C71542', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 7, 'conceptType': 'Disease', 'name': 'B-Cell Acute Lymphoid Leukemia', 'primary_coding_id': 'oncotree:BALL', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.besponsa:0', 'document_id': 'doc:hc.besponsa', 'indication': 'BESPONSA (inotuzumab ozogamicin for injection) is indicated for monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).', 'raw_biomarkers': 'CD22-positive', 'raw_cancer_type': 'B-cell precursor acute lymphoblastic leukemia', 'raw_therapeutics': 'Bespomsa (inotuzumab ozogamicin)'}}, {'id': 8, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Bristol-Myers Squibb Canada. Sprycel (dasatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063441.PDF. Revised November 2021. Accessed June 2025.', 'company': 'Bristol-Myers Squibb Canada', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': '2007-03-22', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-11-03', 'url': 'https://pdf.hres.ca/dpd_pm/00063441.PDF', 'url_drug': 'https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77850', 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 8, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 12, 'type': 'CategoricalVariant', 'name': 'BCR::ABL1', 'genes': [6, 0], 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}, {'name': 'locus', 'value': None}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 84, 'conceptType': 'Drug', 'name': 'Dasatinib', 'primary_coding_id': 'ncit:C38713', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 71, 'conceptType': 'Disease', 'name': 'Chronic Myeloid Leukemia, BCR-ABL1+', 'primary_coding_id': 'oncotree:CMLBCRABL1', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': False, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.sprycel:0', 'document_id': 'doc:hc.sprycel', 'indication': 'SPRYCEL (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved dasatinib for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.', 'raw_biomarkers': 'Philadelphia chromosome positive (Ph+)', 'raw_cancer_type': 'chronic myeloid leukemia (CML) in chronic phase', 'raw_therapeutics': 'Sprycel (dasatinib)'}}, {'id': 9, 'type': 'Statement', 'description': '', 'contributions': [{'id': 0, 'type': 'Contribution', 'agent_id': 0, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}], 'reportedIn': [{'id': 'doc:hc.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [product monograph]. HC.', 'aliases': [], 'citation': 'Knight Therapeutics Inc. Nerlynx (neratinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00062158.PDF. Revised July 2021. Accessed June 2025.', 'company': 'Knight Therapeutics Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': '2019-07-15', 'access_date': '2025-06-13', 'organization_id': 'hc', 'publication_date': '2021-07-16', 'url': 'https://pdf.hres.ca/dpd_pm/00062158.PDF', 'url_drug': None, 'application_number': None}], 'direction': 'supports', 'proposition': {'id': 9, 'type': 'VariantTherapeuticResponseProposition', 'predicate': 'predictSensitivityTo', 'biomarkers': [{'id': 20, 'type': 'CategoricalVariant', 'name': 'HER2-positive', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}, {'name': '_present', 'value': True}]}, {'id': 43, 'type': 'CategoricalVariant', 'name': 'ER negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}, {'id': 44, 'type': 'CategoricalVariant', 'name': 'PR negative', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}, {'name': '_present', 'value': True}]}], 'subjectVariant': {}, 'therapy_group_id': None, 'therapy': {'id': 70, 'conceptType': 'Drug', 'name': 'Neratinib', 'primary_coding_id': 'ncit:C49094', 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, 'conditionQualifier': {'id': 9, 'conceptType': 'Disease', 'name': 'Invasive Breast Carcinoma', 'primary_coding_id': 'oncotree:BRCA', 'mappings': [], 'extensions': [{'name': 'solid_tumor', 'value': True, 'description': 'Boolean value for if this tumor type is categorized as a solid tumor.'}]}}, 'strength': {'id': 0, 'conceptType': 'Evidence', 'name': 'Approval', 'primary_coding_id': 'ncit:C25425', 'mappings': []}, 'indication': {'id': 'ind:hc.nerlynx:0', 'document_id': 'doc:hc.nerlynx', 'indication': 'NERLYNX (neratinib) is indicated for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.', 'initial_approval_date': '', 'initial_approval_url': '', 'description': 'Health Canada approved neratinib for the extended adjuvant treatment of women with early-stage hormone receptor positive and HER2-overexpressed/amplified breast cancer, within one year after completion of trastuzumab-based adjuvant therapy.', 'raw_biomarkers': 'HR+, HER2-overexpressed/amplified', 'raw_cancer_type': 'early-stage breast cancer', 'raw_therapeutics': 'Nerlynx (neratinib)'}}]\n"
     ]
    }
   ],
   "source": [
    "print(dereference_statements(statements, proposition_lookup, strength_lookup, indication_lookup, contribution_lookup, document_lookup))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0288836c-b2e6-4b4d-84c3-ee138a3796e6",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "moalmanac-db",
   "language": "python",
   "name": "moalmanac-db"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
